CAR-T cell therapy debate: the future of lymphoma treatment?
Big data on efficacy and toxicity levels for ibrutinib in CLL
Changing epigenetic markers in CLL patients on ibrutinib
Using PET to determine treatment response in Hodgkin lymphoma
What’s new in minimal residual disease (MRD) detection in myeloma?